--Dr. Mark Ahn Brings ZyGEM Extensive Expertise in Developing and
Commercializing Novel Clinical Products--
SOLANA BEACH, Calif., Feb. 14 /PRNewswire/ -- ZyGEM Corp. Ltd., a leading provider of unique and innovative enzymatic solutions for DNA extraction and detection and other life sciences applications, today announced the appointment of Mark J. Ahn, Ph.D., as Chair of its newly formed Clinical Advisory Board. Dr. Ahn and the new advisory board will assist ZyGEM on expanding its established and new technology platforms into additional clinical medicine applications, with a focus on molecular diagnostics. Dr. Ahn is Professor and Chair, Science & Technology Entrepreneurship at Victoria University of Wellington in New Zealand. Previously, he was President and CEO of Hana Biosciences, Inc. and Vice President of Hematology at Genentech, Inc.
"Mark's expert understanding of drug discovery, development and commercialization will be invaluable as we expand our existing and new technologies into clinical medicine applications," said Paul Kinnon, president and CEO of ZyGEM. "Mark played a key role in helping to build Genentech's oncology business into a world leader before becoming founding CEO of an entrepreneurial cancer firm. His life sciences industry experience spans multiple markets, including health providers, major biopharmaceutical firms, entrepreneurial companies and academia-all potentially important customer segments for ZyGEM's growing product lines. We are delighted to have him on board."
ZyGEM currently develops and markets innovative solutions for life
sciences applications that leverage the properties of unique enzymes in the
company's extensive proprietary culture collection. Its products include
innovative DNA extraction and detection solutions for forensics, livestock
and agriculture, basic research and clinical applications. ZyGEM's
technology is based on more than two decades of research and development
|SOURCE ZyGEM Corp. Ltd.|
Copyright©2008 PR Newswire.
All rights reserved